Literature DB >> 31097999

Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.

Douglas W Thomson1, Daniel Poeckel1, Nico Zinn1, Christina Rau1, Katrin Strohmer1, Anne J Wagner1, Alan P Graves2, Jessica Perrin1, Marcus Bantscheff1, Birgit Duempelfeld1, Viera Kasparcova3, Joshi M Ramanjulu3, G Scott Pesiridis3, Marcel Muelbaier1, Giovanna Bergamini1.   

Abstract

The serine/threonine protein kinase TBK1 (Tank-binding Kinase-1) is a noncanonical member of the IkB kinase (IKK) family. This kinase regulates signaling pathways in innate immunity, oncogenesis, energy homeostasis, autophagy, and neuroinflammation. Herein, we report the discovery and characterization of a novel potent and highly selective TBK1 inhibitor, GSK8612. In cellular assays, this small molecule inhibited toll-like receptor (TLR)3-induced interferon regulatory factor (IRF)3 phosphorylation in Ramos cells and type I interferon (IFN) secretion in primary human mononuclear cells. In THP1 cells, GSK8612 was able to inhibit secretion of interferon beta (IFNβ) in response to dsDNA and cGAMP, the natural ligand for STING. GSK8612 is a TBK1 small molecule inhibitor displaying an excellent selectivity profile and therefore represents an ideal probe to further dissect the biology of TBK1 in models of immunity, neuroinflammation, obesity, or cancer.

Entities:  

Year:  2019        PMID: 31097999      PMCID: PMC6512007          DOI: 10.1021/acsmedchemlett.9b00027

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  38 in total

Review 1.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

2.  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.

Authors:  Marcus Bantscheff; Dirk Eberhard; Yann Abraham; Sonja Bastuck; Markus Boesche; Scott Hobson; Toby Mathieson; Jessica Perrin; Manfred Raida; Christina Rau; Valérie Reader; Gavain Sweetman; Andreas Bauer; Tewis Bouwmeester; Carsten Hopf; Ulrich Kruse; Gitte Neubauer; Nigel Ramsden; Jens Rick; Bernhard Kuster; Gerard Drewes
Journal:  Nat Biotechnol       Date:  2007-08-26       Impact factor: 54.908

3.  The TRAF-associated protein TANK facilitates cross-talk within the IkappaB kinase family during Toll-like receptor signaling.

Authors:  Kristopher Clark; Osamu Takeuchi; Shizuo Akira; Philip Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-23       Impact factor: 11.205

4.  Mice lacking Tbk1 activity exhibit immune cell infiltrates in multiple tissues and increased susceptibility to LPS-induced lethality.

Authors:  Erica Marchlik; Paresh Thakker; Thaddeus Carlson; Zhaozhao Jiang; Mark Ryan; Suzana Marusic; Nadege Goutagny; Wen Kuang; G Roger Askew; Victoria Roberts; Stephen Benoit; Tianhui Zhou; Vincent Ling; Richard Pfeifer; Nancy Stedman; Katherine A Fitzgerald; Lih-Ling Lin; J Perry Hall
Journal:  J Leukoc Biol       Date:  2010-07-22       Impact factor: 4.962

5.  Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.

Authors:  M Paula Longhi; Christine Trumpfheller; Juliana Idoyaga; Marina Caskey; Ines Matos; Courtney Kluger; Andres M Salazar; Marco Colonna; Ralph M Steinman
Journal:  J Exp Med       Date:  2009-06-29       Impact factor: 14.307

6.  IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway.

Authors:  Katherine A Fitzgerald; Sarah M McWhirter; Kerrie L Faia; Daniel C Rowe; Eicke Latz; Douglas T Golenbock; Anthony J Coyle; Sha-Mei Liao; Tom Maniatis
Journal:  Nat Immunol       Date:  2003-05       Impact factor: 25.606

7.  TLR4 ligands induce IFN-alpha production by mouse conventional dendritic cells and human monocytes after IFN-beta priming.

Authors:  Christophe Richez; Kei Yasuda; Amanda A Watkins; Shizuo Akira; Robert Lafyatis; Jean M van Seventer; Ian R Rifkin
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

8.  Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation.

Authors:  Kristopher Clark; Lorna Plater; Mark Peggie; Philip Cohen
Journal:  J Biol Chem       Date:  2009-03-22       Impact factor: 5.157

9.  Novel cross-talk within the IKK family controls innate immunity.

Authors:  Kristopher Clark; Mark Peggie; Lorna Plater; Ronald J Sorcek; Erick R R Young; Jeffrey B Madwed; Joanne Hough; Edward G McIver; Philip Cohen
Journal:  Biochem J       Date:  2011-02-15       Impact factor: 3.857

10.  The selectivity of protein kinase inhibitors: a further update.

Authors:  Jenny Bain; Lorna Plater; Matt Elliott; Natalia Shpiro; C James Hastie; Hilary McLauchlan; Iva Klevernic; J Simon C Arthur; Dario R Alessi; Philip Cohen
Journal:  Biochem J       Date:  2007-12-15       Impact factor: 3.857

View more
  15 in total

1.  TANK-binding kinase 1 inhibitor GSK8612 enhances daunorubicin sensitivity in acute myeloid leukemia cells via the AKT-CDK2 pathway.

Authors:  Siyu Chen; Ming Ni; Tianzhen Hu; Yangguang Gu; Cheng Feng; Chengyun Pan; Siyu Zhang; Shuangshuang Wen; Naiqin Zhao; Weili Wang; Lihong Dai; Jishi Wang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  FACT subunit SUPT16H associates with BRD4 and contributes to silencing of interferon signaling.

Authors:  Dawei Zhou; Zhenyu Wu; Jun-Gyu Park; Guillaume N Fiches; Tai-Wei Li; Qin Ma; Huachao Huang; Ayan Biswas; Luis Martinez-Sobrido; Netty G Santoso; Jian Zhu
Journal:  Nucleic Acids Res       Date:  2022-08-26       Impact factor: 19.160

Review 3.  Regulatory mechanisms of retinal ganglion cell death in normal tension glaucoma and potential therapies.

Authors:  Wen-Cui Shen; Bing-Qing Huang; Jin Yang
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

Review 4.  Targeting TANK-binding kinase 1 (TBK1) in cancer.

Authors:  Or-Yam Revach; Shuming Liu; Russell W Jenkins
Journal:  Expert Opin Ther Targets       Date:  2020-10-05       Impact factor: 6.902

Review 5.  Signaling by cGAS-STING in Neurodegeneration, Neuroinflammation, and Aging.

Authors:  Bindu D Paul; Solomon H Snyder; Vilhelm A Bohr
Journal:  Trends Neurosci       Date:  2020-11-10       Impact factor: 13.837

6.  TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration.

Authors:  Yuchuan Jiang; Siliang Chen; Qiang Li; Junjie Liang; Weida Lin; Jinying Li; Zhilong Liu; Mingbo Wen; Mingrong Cao; Jian Hong
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

Review 7.  Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway.

Authors:  Chunyong Ding; Zilan Song; Ancheng Shen; Tingting Chen; Ao Zhang
Journal:  Acta Pharm Sin B       Date:  2020-03-13       Impact factor: 11.413

Review 8.  The cGAS-STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy.

Authors:  Patrick Kwabena Oduro; Xianxian Zheng; Jinna Wei; Yanze Yang; Yuefei Wang; Han Zhang; Erwei Liu; Xiumei Gao; Mei Du; Qilong Wang
Journal:  Acta Pharm Sin B       Date:  2021-05-20       Impact factor: 11.413

9.  MD2 deficiency prevents high-fat diet-induced AMPK suppression and lipid accumulation through regulating TBK1 in non-alcoholic fatty liver disease.

Authors:  Wu Luo; Lin Ye; Xue-Ting Hu; Mei-Hong Wang; Min-Xiu Wang; Lei-Ming Jin; Zhong-Xiang Xiao; Jian-Chang Qian; Yi Wang; Wei Zuo; Li-Jiang Huang; Guang Liang
Journal:  Clin Transl Med       Date:  2022-03

10.  Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration.

Authors:  David H Drewry; Joel K Annor-Gyamfi; Carrow I Wells; Julie E Pickett; Verena Dederer; Franziska Preuss; Sebastian Mathea; Alison D Axtman
Journal:  J Med Chem       Date:  2021-08-01       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.